11/19
04:30 pm
sgmo
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain [Yahoo! Finance]
11/19
04:15 pm
sgmo
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Medium
Report
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
11/15
06:15 am
sgmo
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/15
12:02 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/14
01:34 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/14
10:12 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at Barclays PLC from $3.00 to $9.00. They now have an "overweight" rating on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at Barclays PLC from $3.00 to $9.00. They now have an "overweight" rating on the stock.
11/12
07:04 pm
sgmo
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates [Yahoo! Finance]
11/12
04:41 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
11/12
04:01 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
High
Report
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
11/5
09:43 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
11/4
04:36 pm
sgmo
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast [Yahoo! Finance]
11/4
04:15 pm
sgmo
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
High
Report
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
11/1
07:53 am
sgmo
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week [Yahoo! Finance]
Medium
Report
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week [Yahoo! Finance]
10/23
03:29 pm
sgmo
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development [Seeking Alpha]
Low
Report
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development [Seeking Alpha]
10/22
12:38 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/22
08:05 am
sgmo
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
High
Report
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
10/21
10:38 am
sgmo
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Iso-Vec... Trifecta Soon? [Seeking Alpha]
Medium
Report
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Iso-Vec... Trifecta Soon? [Seeking Alpha]
9/21
08:48 am
sgmo
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week [Yahoo! Finance]
Medium
Report
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week [Yahoo! Finance]